Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data

Química

• Nutraceutical 100%
• Antifibrotic 90%
• (-)-Epigallocatechin 3-Gallate 82%
• Lipid 54%
• Antiinflammatory 50%
• Antihyperlipidemic 44%
• Pharmacological Metabolism 41%
• Pharmacologic Agent 38%
• (-)-Epicatechin 35%
• Antihypertensive 31%
• Catechin 31%
• Polyphenol 27%
• Insulin Derivative 27%
• Antioxidant Agent 20%
• Green 18%
• Resistance 16%

Medicina y ciencias biológicas

• Non-alcoholic Fatty Liver Disease 85%
• Dietary Supplements 81%
• Catechin 80%
• Liver Diseases 67%
• epigallocatechin gallate 40%
• Lipid Metabolism 30%
• Anti-Inflammatory Agents 23%
• Hypolipidemic Agents 21%
• Organelle Biogenesis 20%
• Polyphenols 17%
• Tea 17%
• Hyperinsulinism 17%
• United States Food and Drug Administration 15%
• Vegetables 15%
• Gastrointestinal Microbiome 15%
• Fruit 15%
• Lipid Peroxidation 14%
• Antihypertensive Agents 14%
• Insulin Resistance 13%
• Hepatocellular Carcinoma 12%
• Antioxidants 11%
• Obesity 11%
• Diet 10%
• Pharmacology 10%
• Inflammation 9%
• Liver 8%
• Therapeutics 7%
• Health 7%